Biotech Investment Landscape Nov 2023
The who is who of biotech trading companies after the biotech bubble burst
This is an inaugural post describing the Biotech Landscape of the companies and sectors I’ve been tracking for many years. In this series of posts, I’ll describe the “who is who of biotech trading companies”, and explain what’s the state of play for different companies after the biotech valuation deflation we’ve experienced in the last two years.
Here is a chart of the sectors and companies I’ve been tracking for the last decade or so:
The different sectors are:
NGS: Next-Generation Sequencing, and associated fields of NGPS (Proteomics) and OM (Optical Mapping).
Single Cell Omics & Spatial Biology: this is a burgeoning field, with lots of competition and M&A positioning as of late and I suspect also in the near future.
GenomicDx: mainly companies with an NGS play in Diagnostics relating to applications using Genomics, mostly cancer but also NIPT.
Liquid Biopsy / Early Cancer Screening Diagnostics: connected to GenomicDx, but here concentrating in liquid biopsy (LQB, e.g. blood) cell-free DNA epigenome profiling for Screening of Cancer for early diagnostics in a cancer-by-cancer scenario, or in Multi-Cancer Early Detection scenarios (MCED). I am more interested in LQB than more traditional GenomicDx, and so I’ll concentrate on the LQB sectors in my posts.
Therapeutic Antibodies / DNA Write / MicrobiomeTx: related fields, which use technologies like Synthetic Biology DNA Write to apply it to therapeutic Antibody products or Microbiome Therapeutics.
Small Molecules and Biologics Big Pharma: these can be very large companies, which I use as bellwethers for big pharma stock.
This is slide number 1 of the http://bit.ly/biotech-stocks-substack slide deck, which is available to annual paid subscribers to this substack.
The higher tier subscribers can also schedule an annual one-to-one Zoom call to discuss the companies I track.